

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Risankizumab for people with previously treated moderately to severely active ulcerative colitis**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During scoping consultation, one stakeholder identified that the mode of administration is a benefit for those with disabilities and those living in remote communities in terms of reducing the need for travel to hospital and could potentially improve adherence.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The mode of administration (subcutaneous injection for disease control) and any potential benefits should be considered by committee. However, there are several oral treatments in the pathway already recommended for moderately to severely active ulcerative colitis, including ozanimod and tofacitinib. It is not anticipated that the mode of administration of risankizumab would offer benefits over and above treatments already recommended at this point in the treatment pathway for moderately to severely active ulcerative colitis.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

None highlighted.

**Approved by Associate Director (name):** ...Emily Crowe.....

**Date:** 11/08/2023